|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
NZ537277A
(en)
|
2002-07-18 |
2008-04-30 |
Crucell Holland Bv |
Recombinant production of mixtures of antibodies
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
ES2408582T3
(es)
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Biblioteca de Fab para la preparación de una mezcla de anticuerpos
|
|
GB2404382B
(en)
|
2003-07-28 |
2008-01-30 |
Oxitec Ltd |
Pest control
|
|
GB2443186A
(en)
|
2006-10-25 |
2008-04-30 |
Oxitec Ltd |
Expression system for mediating alternative splicing
|
|
PL3456190T3
(pl)
*
|
2008-06-27 |
2022-06-06 |
Merus N.V. |
Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
|
|
EP2346994B1
(en)
|
2008-09-30 |
2022-02-16 |
Ablexis, LLC |
Knock-in mice for the production of chimeric antibodies
|
|
BR112012000536A2
(pt)
|
2009-07-08 |
2020-08-11 |
Kymab Limited |
métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
AU2013204019B2
(en)
*
|
2010-02-08 |
2014-02-27 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
SI2501817T2
(sl)
*
|
2010-02-08 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Miš z navadno lahko verigo
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
KR102203727B1
(ko)
|
2010-03-31 |
2021-01-18 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
|
AU2011266843C9
(en)
*
|
2010-06-17 |
2018-03-01 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
JP6482757B2
(ja)
|
2010-07-26 |
2019-03-13 |
トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． |
トランスジェニック動物および使用方法
|
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
SG10201912639SA
(en)
*
|
2010-08-02 |
2020-02-27 |
Regeneron Pharma |
Mice that make binding proteins comprising vl domains
|
|
RS59728B1
(sr)
*
|
2011-08-05 |
2020-02-28 |
Regeneron Pharma |
Humanizovani miševi univerzalnog lakog lanca
|
|
BR112014006394A2
(pt)
*
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
EP2794878B1
(en)
|
2011-12-22 |
2020-03-18 |
F.Hoffmann-La Roche Ag |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
|
RS62023B1
(sr)
*
|
2012-02-01 |
2021-07-30 |
Regeneron Pharma |
Humanizovani glodari koji eksprimiraju teške lance koji sadrže vl domene
|
|
GB2500113A
(en)
|
2012-03-05 |
2013-09-11 |
Oxitec Ltd |
Arthropod male germline gene expression system
|
|
IN2014DN08163A
(https=)
*
|
2012-03-06 |
2015-05-01 |
Regeneron Pharma |
|
|
MX2014011047A
(es)
|
2012-03-16 |
2015-04-08 |
Regeneron Pharma |
Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph.
|
|
SG10201700360VA
(en)
|
2012-03-16 |
2017-03-30 |
Regeneron Pharma |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
KR102228296B1
(ko)
|
2012-03-16 |
2021-03-17 |
리제너론 파마슈티칼스 인코포레이티드 |
히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
SI2838917T1
(sl)
|
2012-04-20 |
2019-11-29 |
Merus Nv |
Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
|
|
RU2014153674A
(ru)
*
|
2012-06-05 |
2016-07-27 |
Регенерон Фармасьютикалз, Инк. |
Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
|
|
BR112015000167B1
(pt)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
|
|
CN103571872B
(zh)
*
|
2012-08-09 |
2016-11-23 |
山东国际生物科技园发展有限公司 |
一种能够表达人抗体的转基因动物的制备方法
|
|
EP3470431A1
(en)
|
2012-09-27 |
2019-04-17 |
Merus N.V. |
Bispecific igg antibodies as t cell engagers
|
|
GB201303932D0
(en)
|
2013-03-05 |
2013-04-17 |
Oxitec Ltd |
Muscle actin promoter
|
|
WO2014160202A1
(en)
*
|
2013-03-13 |
2014-10-02 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
PL2968440T3
(pl)
|
2013-03-15 |
2019-12-31 |
Zymeworks Inc. |
Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
DE112014004537T5
(de)
|
2013-10-01 |
2016-07-21 |
Kymab Limited |
Tiermodelle und therapeutische Moleküle
|
|
ES2715949T3
(es)
*
|
2013-10-15 |
2019-06-07 |
Regeneron Pharma |
Animales con IL-15 humanizada
|
|
RU2729194C2
(ru)
|
2013-12-27 |
2020-08-05 |
Займворкс Инк. |
Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
|
|
EP3786186A1
(en)
|
2014-02-28 |
2021-03-03 |
Merus N.V. |
Antibodies that bind egfr and erbb3
|
|
IL301147A
(en)
|
2014-02-28 |
2023-05-01 |
Merus Nv |
An antibody that binds to ErbB-2 and ErbB-3
|
|
KR102276752B1
(ko)
|
2014-03-21 |
2021-07-13 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
GB2526867A
(en)
*
|
2014-06-05 |
2015-12-09 |
Oxitec Ltd |
Gene expression system
|
|
AU2015318556C1
(en)
|
2014-09-17 |
2021-01-07 |
Zymeworks Bc Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
SI3115376T1
(sl)
|
2015-07-10 |
2018-12-31 |
Merus N.V. |
Humana protitelesa, ki vežejo CD3
|
|
US20170058052A1
(en)
|
2015-08-24 |
2017-03-02 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
|
CA3002957A1
(en)
|
2015-10-23 |
2017-04-27 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Binding molecules that inhibit cancer growth
|
|
EP3384030A4
(en)
|
2015-12-03 |
2019-07-03 |
Trianni, Inc. |
IMPROVED IMMUNOGLULINIVITY
|
|
AU2017213633B2
(en)
|
2016-02-04 |
2023-08-03 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
|
HUE061619T2
(hu)
*
|
2016-06-03 |
2023-07-28 |
Regeneron Pharma |
Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók
|
|
WO2018029534A1
(en)
|
2016-08-12 |
2018-02-15 |
Oxitec Ltd. |
A self-limiting, sex-specific gene and methods of using
|
|
BR112019005895A2
(pt)
|
2016-09-23 |
2019-06-11 |
Merus N.V. |
moléculas de ligação que modulam uma atividade biológica expressa por uma célula
|
|
CN110637083A
(zh)
*
|
2017-03-20 |
2019-12-31 |
华盛顿大学 |
细胞及其使用和制备方法
|
|
AU2018246873B2
(en)
|
2017-03-31 |
2021-05-06 |
Merus B.V. |
ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
|
|
AU2018246872C1
(en)
|
2017-03-31 |
2023-05-18 |
Merus B.V. |
ErbB-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbB-3, for treatment of an individual with an erbB-2, erbB-2/erbB-3 positive tumour
|
|
WO2018212656A1
(en)
|
2017-05-17 |
2018-11-22 |
Merus N.V. |
Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
|
|
EA202090003A1
(ru)
|
2017-07-06 |
2020-06-18 |
Мерус Н.В. |
Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
|
|
EP3649155A1
(en)
|
2017-07-06 |
2020-05-13 |
Merus N.V. |
Bispecific anti pd1-anti tim3 antibodies
|
|
EA202090005A1
(ru)
|
2017-07-06 |
2020-06-18 |
Мерус Н.В. |
Антитела, модулирующие биологическую активность, проявляемую клеткой
|
|
GB201710984D0
(en)
*
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|
|
CN118580366A
(zh)
|
2017-08-09 |
2024-09-03 |
美勒斯公司 |
结合EGFR和cMET的抗体
|
|
CN111432838A
(zh)
|
2017-12-01 |
2020-07-17 |
美勒斯公司 |
使用双特异性抗体和il-15进行联合治疗
|
|
DK4140297T3
(da)
*
|
2017-12-05 |
2025-06-23 |
Regeneron Pharma |
Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf
|
|
TWI849895B
(zh)
|
2018-02-09 |
2024-07-21 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
WO2019190922A1
(en)
|
2018-03-24 |
2019-10-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
|
|
AR117409A1
(es)
|
2018-03-29 |
2021-08-04 |
Oxitec Ltd |
Noctuidas autolimitantes
|
|
MX2020010267A
(es)
|
2018-03-30 |
2020-11-06 |
Merus Nv |
Anticuerpo multivalente.
|
|
CN108624622A
(zh)
*
|
2018-05-16 |
2018-10-09 |
湖南艾佳生物科技股份有限公司 |
一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
|
|
KR102480493B1
(ko)
*
|
2018-06-08 |
2022-12-21 |
크리스탈 바이오사이언스 주식회사 |
동일한 경쇄 i을 갖는 다양한 항체를 생산하기 위한 트랜스제닉 동물
|
|
IL318469A
(en)
|
2018-06-14 |
2025-03-01 |
Regeneron Pharma |
Non-human animals capable of reorganizing transgenic DH-DH, and their uses
|
|
US11873338B2
(en)
|
2018-12-20 |
2024-01-16 |
Merus N.V. |
CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease
|
|
WO2020132557A1
(en)
|
2018-12-21 |
2020-06-25 |
Compass Therapeutics Llc |
Transgenic mouse expressing common human light chain
|
|
US20220380440A1
(en)
|
2018-12-31 |
2022-12-01 |
Merus N.V. |
Truncated multivalent multimers
|
|
CN113227132A
(zh)
*
|
2018-12-31 |
2021-08-06 |
美勒斯公司 |
混合的结合域
|
|
US11008395B2
(en)
|
2019-01-22 |
2021-05-18 |
Bristol Myers-Squibb Company |
Antibodies against IL-7R alpha subunit and uses thereof
|
|
MX2021009769A
(es)
|
2019-02-14 |
2021-09-08 |
Merus Nv |
Produccion de composiciones que comprenden dos o mas anticuerpos.
|
|
CA3130248A1
(en)
|
2019-02-14 |
2020-08-20 |
Merus N.V. |
Combinations of binding moieties that bind egfr, her2 and her3.
|
|
EP3927832A4
(en)
|
2019-02-18 |
2022-11-30 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
|
|
TW202546002A
(zh)
|
2019-03-29 |
2025-12-01 |
荷蘭商美勒斯公司 |
Cd3結合分子
|
|
TWI862565B
(zh)
|
2019-04-04 |
2024-11-21 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
US20210054049A1
(en)
|
2019-05-09 |
2021-02-25 |
Merus N.V. |
Variant domains for multimerizing proteins and separation thereof
|
|
CA3144956A1
(en)
*
|
2019-07-01 |
2021-01-07 |
Trianni, Inc. |
Transgenic mammals and methods of use
|
|
WO2021006199A1
(ja)
*
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
WO2021020416A1
(ja)
|
2019-07-30 |
2021-02-04 |
小野薬品工業株式会社 |
二重特異性抗体
|
|
EP3772518A1
(en)
|
2019-08-07 |
2021-02-10 |
Merus N.V. |
Modified human variable domains
|
|
AU2020331879C1
(en)
|
2019-08-19 |
2025-11-27 |
Merus B.V. |
Treatment of cancer with a combination of an antibody that binds LGR5 and EGFR and a topoisomerase I inhibitor.
|
|
GB201912008D0
(en)
|
2019-08-21 |
2019-10-02 |
Cambridge Entpr Ltd |
Antibody
|
|
JP7726881B2
(ja)
|
2019-12-02 |
2025-08-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
|
|
CN116199780A
(zh)
|
2019-12-24 |
2023-06-02 |
美勒斯公司 |
TGF-β-RII结合蛋白质
|
|
CN116407626A
(zh)
|
2020-01-29 |
2023-07-11 |
美勒斯公司 |
用于调节免疫细胞衔接效应的手段和方法
|
|
MX2022013182A
(es)
|
2020-04-24 |
2023-01-16 |
Merus Nv |
Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr.
|
|
KR20230018439A
(ko)
|
2020-06-02 |
2023-02-07 |
바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 |
공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
|
|
CA3187680A1
(en)
|
2020-09-11 |
2022-03-17 |
Yashu Liu |
Identification and production of antigen-specific antibodies
|
|
JP7714992B2
(ja)
*
|
2020-10-02 |
2025-07-30 |
小野薬品工業株式会社 |
二重特異性抗体を有効成分として含む医薬組成物
|
|
CA3202006A1
(en)
|
2020-12-15 |
2022-06-23 |
Leonardo Andres SIRULNIK |
Treatment of cancers with an antibody that binds lgr5 and egfr
|
|
WO2022132943A1
(en)
|
2020-12-16 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized fc alpha receptors
|
|
JP2023554422A
(ja)
|
2020-12-16 |
2023-12-27 |
メルス ナムローゼ フェンノートシャップ |
がんの治療のための多重特異性抗体
|
|
AU2021401712A1
(en)
|
2020-12-18 |
2023-07-06 |
Merus N.V. |
Antibody composition
|
|
CA3165366A1
(en)
|
2020-12-23 |
2022-06-30 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses thereof
|
|
CN120504741A
(zh)
|
2021-10-06 |
2025-08-19 |
美勒斯公司 |
使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症
|
|
EP4469476A1
(en)
|
2022-01-25 |
2024-12-04 |
Merus N.V. |
Combination therapy for the treatment of cancer
|
|
JP2025509312A
(ja)
|
2022-03-07 |
2025-04-11 |
メルス ナムローゼ フェンノートシャップ |
ＥＧＦＲ及びｃＭＥＴに結合する抗体を含む併用療法
|
|
KR20240151848A
(ko)
|
2022-03-07 |
2024-10-18 |
메뤼스 엔.페. |
Egfr 및 cmet에 결합하는 항체를 사용한 치료
|
|
GB202216503D0
(en)
|
2022-11-05 |
2022-12-21 |
Quadrucept Bio Ltd |
Non-human vertebrates & cells
|
|
GB202217978D0
(en)
|
2022-11-30 |
2023-01-11 |
Petmedix Ltd |
Rodents expressing a common light chain
|
|
KR20250124833A
(ko)
|
2022-12-23 |
2025-08-20 |
메뤼스 엔.페. |
적어도 egfr에 결합하는 항체 및 면역 관문 저해제를 사용한 암의 병용 치료
|
|
EP4642443A1
(en)
|
2022-12-28 |
2025-11-05 |
Merus N.V. |
Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
|
|
WO2025105961A1
(en)
|
2023-11-17 |
2025-05-22 |
Merus N.V. |
COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET.
|
|
WO2026030428A2
(en)
|
2024-08-01 |
2026-02-05 |
Regeneron Pharmaceuticals, Inc. |
Prostate-specific antigen peptides and uses thereof
|
|
WO2026035843A2
(en)
|
2024-08-06 |
2026-02-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
|